Effective treatments for amyotrophic lateral sclerosis (ALS) have remained elusive. Only
riluzole, a drug thought to affect glutamate metabolism, improves survival albeit to modest …

Background Amyotrophic lateral sclerosis is a rapidly progressive neurodegenerative
disorder characterised by loss of motor neurons leading to severe weakness and death from …

Objective: To use a historical placebo control design to determine whether lithium carbonate
slows progression of amyotrophic lateral sclerosis (ALS). Methods: A phase II trial was …

In January, 2008 an international web-based patient and family led study (http://alslithium.
atspace. com) was initiated to test the results of (Fornai et al. 2008) that lithium, and/or …

The treatment of amyotrophic lateral sclerosis (ALS) is hampered by a lack of drugs that
intervene in the pathogenetic mechanisms of the disorder. Only one treatment that tackles …

Dear Sir We read with interest the review paper by Mitchell et al.(1) describing the outcomes
of amyotrophic lateral sclerosis (ALS) patients treated with riluzole. The authors show a clear …

Justified disappointment has followed the publication in The Lancet Neurology of the paper
by Gordon and coworkers, who reported negative results from a large phase III randomised …

My husband, Rahul Desikan, MD, PhD, was diagnosed at age 38 years with bulbar
amyotrophic lateral sclerosis (ALS), a fatal, progressive neurodegenerative illness that …

The Edaravone (MCI-186) ALS 19 Study Group1 reported on the safety and efficacy of
edaravone in a phase 3 study of patients with earlystage amyotrophic lateral sclerosis. The …

When choosing the drug dose for a trial that aims to detect a disease-modifying effect, the U-
shaped or bellshaped dose–response effect must be taken into account: low concentrations …